摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]-2-prop-2-yn-1-yl-4-pentynoic acid | 854771-87-2

中文名称
——
中文别名
——
英文名称
2-[4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]-2-prop-2-yn-1-yl-4-pentynoic acid
英文别名
2-[4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]-2-prop-2-yn-1-ylpent-4-ynoic acid;[4-({3-[3-BENZOYL-8-(TRIFLUOROMETHYL)QUINOLIN-4-YL]PHENOXY}METHYL)PHENYL]-2-PROP-2-YN-1-YLPENT-4-YNOIC ACID;2-[4-[[3-[3-Benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]phenyl]-2-prop-2-ynylpent-4-ynoic acid
2-[4-({3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy}methyl)phenyl]-2-prop-2-yn-1-yl-4-pentynoic acid化学式
CAS
854771-87-2
化学式
C38H26F3NO4
mdl
——
分子量
617.624
InChiKey
AUZXYUZQKUMYSD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8
  • 重原子数:
    46
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    76.5
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

  • 作为产物:
    参考文献:
    名称:
    Carboxylic acid based quinolines as liver X receptor modulators that have LXRβ receptor binding selectivity
    摘要:
    A series of potent and binding selective LXR beta agonists was developed using the previously reported non-selective LXR ligand WAY-254011 as a structural template. With the aid of molecular modeling, it was found that 2,3-diMe-Ph, 2,5-diMe-Ph, and naphthalene substituted quinoline acetic acids (such as quinoline 33, 37, and 38) showed selectivity for LXR beta over LXR alpha in binding assays. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.11.013
点击查看最新优质反应信息

文献信息

  • Quinolines useful in treating cardiovascular disease
    申请人:Collini D. Michael
    公开号:US20050131014A1
    公开(公告)日:2005-06-16
    This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.
    本发明提供了式I化合物的用途,它们在治疗或抑制LXR介导的疾病中是有用的。
  • QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE
    申请人:Wyeth, A Corporation of the State of Delaware
    公开号:EP1692111A2
    公开(公告)日:2006-08-23
  • JP2007516258A
    申请人:——
    公开号:JP2007516258A
    公开(公告)日:2007-06-21
  • US7576215B2
    申请人:——
    公开号:US7576215B2
    公开(公告)日:2009-08-18
  • [EN] QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE<br/>[FR] QUINOLINES CONVENANT POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
    申请人:WYETH CORP
    公开号:WO2005058834A2
    公开(公告)日:2005-06-30
    This invention provides compounds of formula (I) that are useful in the treatment or inhibition of LXR mediated diseases.
查看更多